Knight Therapeutics reports uncertain financial outlook for 2024

Knight Therapeutics Inc. held a conference call on March 20, 2025, to discuss their earnings for the fourth quarter of 2024. The call featured key company leaders, including Samira Sakhia, the President and CEO, and Arvind Utchanah, the CFO. During the call, Sakhia welcomed attendees and provided an overview of the quarter’s performance. She emphasized that the discussion would include forward-looking statements, which carry risks and uncertainties. The company is not obligated to update these statements unless required by law. Analysts from various financial firms participated in the call, but questions were limited to them only. Those interested in reaching out after the call were encouraged to contact Knight’s Investor Relations department through email or phone. The call remained focused on Knight Therapeutics’ financial results and strategic plans moving forward. It aimed to provide insights into the company’s goals and expectations for the future.